Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial

Једноставна страница ставке
dc.citation.spage2001178
dc.citation.volume65
dc.contributor.authorAmerikanou, Charalampia
dc.contributor.authorKanoni, Stavroula
dc.contributor.authorKaliora, Andriana C.
dc.contributor.authorBarone, Angela
dc.contributor.authorBjelan, Mladen
dc.contributor.authorD’Auria, Giuseppe
dc.contributor.authorGioxari, Aristea
dc.contributor.authorJosé Gosalbes, María
dc.contributor.authorMouchti, Sofia
dc.contributor.authorStathopoulou, Maria G.
dc.contributor.authorSoriano, Beatriz
dc.contributor.authorStojanoski, Stefan
dc.contributor.authorBanerjee, Rajarshi
dc.contributor.authorHalabalaki, Maria
dc.contributor.authorMikropoulou, Eleni V.
dc.contributor.authorKannt, Aimo
dc.contributor.authorLamont, John
dc.contributor.authorLlorens, Carlos
dc.contributor.authorMarascio, Fernando
dc.contributor.authorMarascio, Miriam
dc.contributor.authorRoig, Francisco J.
dc.contributor.authorSmyrnioudis, Ilias
dc.contributor.authorVarlamis, Iraklis
dc.contributor.authorVisvikis-Siest, Sophie
dc.contributor.authorVukic, Milan
dc.contributor.authorMilic, Natasa
dc.contributor.authorMedic-Stojanoska, Milica
dc.contributor.authorCesarini, Lucia
dc.contributor.authorCampolo, Jonica
dc.contributor.authorGastaldelli, Amalia
dc.contributor.authorDeloukas, Panos
dc.contributor.authorTrivella, Maria Giovanna
dc.contributor.authorFrancino, M. Pilar
dc.contributor.authorDedoussis, George V.
dc.date.accessioned2023-06-01T11:09:55Z
dc.date.available2023-06-01T11:09:55Z
dc.date.issued2021
dc.description.abstractScope Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with poor therapeutic strategies. Mastiha possesses antioxidant/anti-inflammatory and lipid-lowering properties. The authors investigate the effectiveness of Mastiha as a nonpharmacological intervention in NAFLD. Methods and Results Ninety-eight patients with NAFLD in three countries (Greece, Italy, Serbia) are randomly allocated to either Mastiha or Placebo for 6 months, as part of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The authors assess NAFLD severity via magnetic resonance imaging (MRI) scanning and LiverMultiScan technique and evaluate the effectiveness of Mastiha through medical, anthropometric, biochemical, metabolomic, and microbiota assessment. Mastiha is not superior to Placebo on changes in iron-corrected T1 (cT1) and Liver Inflammation Fibrosis score (LIF) in entire patient population; however, after BMI stratification (BMI ≤ 35 kg m-2 and BMI > 35 kg m-2), severely obese patients show an improvement in cT1 and LIF in Mastiha versus Placebo. Mastiha increases dissimilarity of gut microbiota, as shown by the Bray-Curtis index, downregulates Flavonifractor, a known inflammatory taxon and decreases Lysophosphatidylcholines-(LysoPC) 18:1, Lysophosphatidylethanolamines-(LysoPE) 18:1, and cholic acid compared to Placebo. Conclusion Mastiha supplementation improves microbiota dysbiosis and lipid metabolite levels in patients with NAFLD, although it reduces parameters of liver inflammation/fibrosis only in severely obese patients.
dc.identifier.doi10.1002/mnfr.202001178
dc.identifier.urihttps://vaseljena.ues.rs.ba/handle/123456789/254
dc.language.isoen
dc.publisherWiley
dc.sourceMolecular Nutrition & Food Research
dc.titleEffect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial
dc.typeArticle
Датотеке
Оригинални завежљај
Сада се приказује 1 - 1 од 1
Сличица
Име:
Effect of Mastiha supplementation on NAFLD The.pdf
Величина:
892.4 KB
Формат:
Adobe Portable Document Format
Опис:
Преузимање
Свежањ лиценце
Сада се приказује 1 - 1 од 1
Сличица
Име:
license.txt
Величина:
1.71 KB
Формат:
Item-specific license agreed to upon submission
Опис:
Преузимање
Колекције
Технолошки факултет [Научни радови] / Faculty of Technology [Scientific papers]